WallStSmart

Curanex Pharmaceuticals Inc Common Stock (CURX)vsBeOne Medicines AG (ONC)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

ONC leads profitability with a 13.9% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 68/100 (B-).

CURX

Avoid

23

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 8.5
Piotroski: 3/9Altman Z: 18.01

ONC

Strong Buy

68

out of 100

Grade: B-

Growth: 10.0Profit: 7.5Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: 0.75
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CURX.

ONCUndervalued (+80.8%)

Margin of Safety

+80.8%

Fair Value

$1828.58

Current Price

$390.94

$1437.64 discount

UndervaluedFair: $1828.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CURX3 strengths · Avg: 9.7/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
18.0110/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

ONC4 strengths · Avg: 9.3/10
Revenue GrowthGrowth
33.8%10/10

Revenue surging 33.8% year-over-year

EPS GrowthGrowth
212.5%10/10

Earnings expanding 212.5% YoY

Debt/EquityHealth
0.209/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.718/10

Growing faster than its price suggests

Areas to Watch

CURX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.53M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

ONC2 concerns · Avg: 2.0/10
P/E RatioValuation
51.2x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.752/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CURX

The strongest argument for CURX centers on Price/Book, Altman Z-Score, Debt/Equity.

Bull Case : ONC

The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 33.8% demonstrates continued momentum. PEG of 0.71 suggests the stock is reasonably priced for its growth.

Bear Case : CURX

The primary concerns for CURX are Revenue Growth, EPS Growth, Market Cap.

Bear Case : ONC

The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 51.2x leaves little room for execution misses.

Key Dynamics to Monitor

CURX profiles as a value stock while ONC is a growth play — different risk/reward profiles.

ONC is growing revenue faster at 33.8% — sustainability is the question.

ONC generates stronger free cash flow (474M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ONC scores higher overall (68/100 vs 23/100) and 33.8% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Curanex Pharmaceuticals Inc Common Stock

HEALTHCARE · BIOTECHNOLOGY · USA

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. The company is headquartered in Jericho, New York.

BeOne Medicines AG

HEALTHCARE · BIOTECHNOLOGY · USA

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

Want to dig deeper into these stocks?